Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy Andrea Koch, MD, Helena Fohlin, MSc, Sverre Sörenson, MD, PhD Journal of Thoracic Oncology Volume 4, Issue 3, Pages 326-332 (March 2009) DOI: 10.1097/JTO.0b013e31819578c8 Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 Exclusions after identification of 313 patients with non-small cell lung cancer (NSCLC) stage IIIB/IV treated with palliative first-line chemotherapy. Journal of Thoracic Oncology 2009 4, 326-332DOI: (10.1097/JTO.0b013e31819578c8) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 2 Kaplan-Meier survival curves when patients were grouped according to C-reactive protein (CRP) levels. Journal of Thoracic Oncology 2009 4, 326-332DOI: (10.1097/JTO.0b013e31819578c8) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 3 Kaplan-Meier survival curves for current smokers versus current nonsmokers at start of chemotherapy. Journal of Thoracic Oncology 2009 4, 326-332DOI: (10.1097/JTO.0b013e31819578c8) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 4 Survival when patients were grouped by combining C-reactive protein (CRP) and smoking status at start of chemotherapy. Journal of Thoracic Oncology 2009 4, 326-332DOI: (10.1097/JTO.0b013e31819578c8) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions